Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Merger
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Merger
Reset All
